Cost Plus Drugs Marketplace (For Business)

💡 MultiCare & Cost Plus Drugs: A Model for Affordable Medication Access💡 Excited to share that Modern Healthcare recently featured MultiCare Health System’s strategic partnership with Mark Cuban Cost Plus Drug Co.! This collaboration has been instrumental in saving $1.5 million on essential medications—funds that we are reinvesting into new service lines, technology, and expanded patient care. At MultiCare, we recognize that rising drug costs demand innovative solutions. By integrating transparent pricing models and exploring disruptive strategies, we are making medications more accessible while optimizing our pharmacy supply chain. Cost Plus Drugs’ commitment to affordability and visibility aligns with our mission to drive sustainable cost savings without compromising patient care. The future of pharmacy lies in innovation, accessibility, and transparency—and we’re just getting started! How is your organization tackling drug pricing challenges? Let’s connect and share insights! #PharmacySupplyChain #HealthcareInnovation #DrugPricing #PharmacyLeadership #ValueBasedCare #CostPlusDrugs #MultiCare Mark Cuban Cost Plus Drug Company, PBC Alan Bowe Mark Cuban

My fellow OBGYNS - This is the biggest weapon we've ever had against syphilis in pregnancy! You can now stock Penicillin G (Benzathine) in your office for just $15 per shot! No more waiting and hoping they actually go to the health department! Thanks to Mark Cuban's Mark Cuban Cost Plus Drug Company, PBC!

Tyson Frodin, AVP of Pharmacy at MultiCare Health System, describes a partnership paying big dividends! Tyson shares how leveraging strategic partnerships like Mark Cuban Cost Plus Drug Company, PBC has transformed their approach to pharmacy management. 𝐃𝐚𝐭𝐚-𝐃𝐫𝐢𝐯𝐞𝐧 𝐒𝐚𝐯𝐢𝐧𝐠𝐬: By leveraging data analytics, MultiCare identified Mark Cuban Cost Plus Drugs as a disruptive partner to bypass traditional middlemen like wholesalers and GPOs. This approach saved over $1 million in just six months, allowing reinvestment in patient care and innovation. 340𝐁 𝐚𝐧𝐝 𝐑𝐞𝐭𝐚𝐢𝐥 𝐒𝐲𝐧𝐞𝐫𝐠𝐲: MultiCare's 12 retail pharmacies—half operating under 340B—have benefited significantly. Through careful analysis of WAC spend and Mark Cuban's pricing catalog, they optimized drug purchasing, turning cost efficiencies into accumulations for 340B purchases. 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐋𝐞𝐚𝐝𝐞𝐫𝐬𝐡𝐢𝐩: Tyson emphasized MultiCare’s commitment to forward-thinking strategies, automation, and direct partnerships to navigate disruptions like supply chain challenges and inflation. Thank you, Tyson, for sharing! More of this conversation will be released very soon! Stay tuned. Tyson is a Provider member of the Council of Pharmacy Executives and Suppliers (CPES). Alan Bowe /Mark Cuban If you want to learn how to get involved or support CPES, please reach out!

🌟 Innovating Pharmacy Supply Chains with Cost Plus Drugs 🌟 As we step into 2025, the healthcare industry continues to grapple with complex challenges, from rising costs to critical drug shortages. At MultiCare Health System, we are proud to be recognized for our partnership with Mark Cuban’s Cost Plus Drugs — a collaboration that is driving real change and reshaping pharmacy supply chain strategies. Mark Cuban's vision for Cost Plus Drugs exemplifies what true disruption looks like: cutting through the complexity of inflated drug pricing and outdated systems to deliver affordable medications directly to those who need them most. Through this innovative partnership, MultiCare has achieved remarkable savings while ensuring access to critical medications for our patients. This isn’t just about cost savings; it’s about reimagining how we approach healthcare supply chains to create sustainable, patient-centered solutions. By embracing bold ideas and strategic partnerships, we’re building a better future for healthcare. 👏 A huge thank you to Mark Cuban and his incredible team for their commitment to transforming the pharmaceutical landscape! Together, we’re making healthcare more accessible, affordable, and equitable for all. 💡 How is your organization thinking big to address healthcare challenges in 2025? I’d love to hear your thoughts and ideas in the comments below. #HealthcareInnovation #PharmacySupplyChain #CostPlusDrugs #Partnership #MultiCareHealthSystem Mark Cuban Cost Plus Drug Company, PBC Mark Cuban Alex Oshmyansky, MD, PhD MultiCare Health System

Thrilled to share MultiCare Health System’s innovative partnership with Mark Cuban Cost Plus Drug Company, which was recently featured in Becker’s! 🏥💊 Through this collaboration, MultiCare has saved over $1 million on 125 generic medications from April to October alone. By leveraging Cost Plus Drugs’ transparent pricing model and utilizing data analytics, we've identified opportunities to drive significant value — not just in cost savings, but in reinvesting those dollars into initiatives that improve care delivery and patient outcomes. These savings represent just a fraction of our $350 million annual drug budget, but they’re already fueling new opportunities: * Supporting new service lines *Investing in cutting-edge technology and automation *Improving access to care and patient experiences This partnership also enhances our approach to managing drug shortages, helping reduce spend on replacement therapies by over 50% this year. It’s a perfect example of how pharmacy leaders can tackle healthcare’s toughest challenges through strategy, innovation, and collaboration. Mark Cuban Mark Cuban Cost Plus Drug Company, PBC MultiCare Health System

Pharmacy Supply Chain Breakthrough: $1 Million Saved in 6 Months—and We're Just Getting Started! The pharmacy supply chain is a dynamic landscape where innovation isn’t just an advantage—it’s a necessity. At MHS, we achieved a remarkable milestone by saving over $1 million in just six months through a strategic partnership with Mark Cuban Cost Plus Drug Company, PBC —and we’re just getting started! This success wasn’t without its challenges. Balancing bold cost-saving strategies with the complexities of GPO obligations, 340B program requirements, and wholesaler agreements required a deliberate focus on pharmacy business strategy. By fostering strategic partnerships and embracing unconventional collaborations, we aligned our approach across finance, clinical, and supply chain teams to ensure compliance while delivering meaningful savings. This initiative demonstrates that innovation, when paired with thoughtful strategy and collaboration, can drive transformative results. As healthcare leaders, we’re continually tasked with finding creative ways to deliver value. I’m curious—what innovative strategies or partnerships have you explored to optimize pharmacy operations and achieve similar success? Let’s connect, exchange ideas, and spark new opportunities for growth. #PharmacySupplyChain #PharmacyBusinessStrategy #StrategicPartnerships #HealthcareInnovation #CostSavings #340BOptimization Mark Cuban

Penn Medicine is teaming up with Mark Cuban Cost Plus Drug Company, PBC through a first-of-its-kind collaboration for purchase of the most common generic drugs dispensed in our retail pharmacies, allowing us to reinvest those savings in new care innovations. Health systems everywhere face rising costs on many different fronts. But this joint effort goes beyond cost savings, says Mark Cuban. "It's about empowering healthcare providers like Penn Medicine to deliver superior care by removing financial barriers to essential medications." The new partnership is part of Penn Medicine’s mission to give patients more choices and set new standards for medicine. Learn more: http://spr.ly/6040Qyvby Nishaminy Kasbekar, BS, PharmD, FASHP